Alan Xiao

Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic‐derived dose justification for phase 3 studies in patients with nosocomial pneumonia

Alan Xiao, Benjamin Miller, Jennifer A. Huntington et al. · The Journal of Clinical Pharmacology · 2015 · 151 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Inhibition of capsaicin‐induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK‐0974)

Simon Sinclair, Stefanie A. Kane, Bart Van der Schueren et al. · British Journal of Clinical Pharmacology · 2009 · 87 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Factors Affecting Scale Inhibitor Retention in Carbonate-Rich Formation During Squeeze Treatment

Amy T. Kan, Gongmin Fu, Mason B. Tomson et al. · SPE Journal · 2004 · 77 citations

Natural Sciences, Chemistry, Petroleum Engineering +15

Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections

Gurudatt Chandorkar, Alan Xiao, Samer Mouksassi et al. · The Journal of Clinical Pharmacology · 2014 · 64 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15

PK/PD Target Attainment With Ceftolozane/Tazobactam Using Monte Carlo Simulation in Patients With Various Degrees of Renal Function, Including Augmented Renal Clearance and End-Stage Renal Disease

Alan Xiao, Luzelena Caro, Myra W. Popejoy et al. · Infectious Diseases and Therapy · 2016 · 35 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17